Dokmak Amr, Almeqdadi Mohammad, Trivedi Hirsh, Krishnan Sandeep
Division of Medicine, St. Elizabeth's Medical Center, Brighton, MA 02135, United States.
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States.
World J Hepatol. 2019 Jul 27;11(7):562-573. doi: 10.4254/wjh.v11.i7.562.
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions.
非酒精性脂肪性肝病（NAFLD）是西方世界最常见的慢性肝病形式。在男性、随着年龄增长、肥胖以及胰岛素抵抗人群中更为普遍。除了减肥之外，治疗选择有限。抗糖尿病药物的使用已经过研究，但结果不一。在本综述中，我们讨论抗糖尿病药物在NAFLD管理中的应用，特别关注钠-葡萄糖协同转运蛋白2抑制剂。我们详细阐述支持其使用的证据，并讨论局限性和未来方向。
